Immunomax enhances immune defense against viral and bacterial infections. Immunopharmacological mechanisms of action of the drug consist in the fact that Immunomax activates the following links of the immune system:
- NK cells, which in 2-3 hours, after exposure to Immunomax, intensively express the activation molecules of CD69. The cytolytic activity of NK cells increases 3-fold;
- circulating monocytes 2-4 hours after activation by Immunomax begin to secrete cytokines: interleukin-8, interleukin-1β and tumor necrosis factor alpha;
- neutrophilic granulocytes are activated by means of monocytes, the drug does not directly affect neutrophilic granulocytes. Secreted by monocytes, interleukin-8 induces activation of neutrophilic granulocytes, which is clearly manifested 24 hours after exposure to Immunomax;
- tissue macrophages, which is manifested in a change in the morphology of these cells, increased production of bactericidal substances, changes in the activity of 5'-nucleotidase;
- the formation of antibodies against foreign antigens, soluble and corpuscular;
Immunomax enhances protection against infections caused by viruses (human papillomavirus, herpes simplex virus, parvovirus, carnivorous plague virus, etc.) or bacteria (Escherichia coli, Salmonella, Staphylococcus, Chlamydia, Mycoplasma, Ureaplasma, etc.). This effect of the drug is manifested in adults and newborns with the introduction of Immunomax in various ways: intramuscularly, intravenously, intraperitoneally, re os.